NDAORALSOLUTION
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
LOPRESSOR (metoprolol tartrate) by Rubicon Biotechnology is 12. First approved in 2025.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPRESSOR (metoprolol tartrate) is a beta-1 selective adrenergic receptor blocking agent indicated for hypertension, angina pectoris, and heart failure. It works by competitively antagonizing catecholamines at cardiac adrenergic sites, reducing heart rate, cardiac output, and myocardial oxygen demand. The oral solution formulation was approved April 2025 by Rubicon Biotechnology.
$0.37MPart D
LAUNCHEarly-stage launch with modest Part D penetration (940 claims, 2023) suggests limited market adoption to date; commercial team focus will be on rapid uptake and market education.
Mechanism of Action
12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular…
Worked on LOPRESSOR at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.